News & Updates

Read about select research advances supported by NICHD in 2024, including work on women’s health, child and adolescent health, medical rehabilitation, health disparities, and more.

NIH has announced winners of its competition to accelerate the development of diagnostic and monitoring technologies to improve fetal health outcomes.

NIH has announced finalists in its competition to accelerate the development of diagnostic and monitoring technologies to improve fetal health outcomes.

Researchers linked malformations in stillborn infants to copy number variants—lengths of DNA in which hereditary material is duplicated or deleted. What they learned could lead provide information helpful to parents and for pregnancy care.

Depression in early and mid-pregnancy seems to age the placenta more rapidly than not experiencing depression during pregnancy. Premature placental aging could account for higher rates of low birth weight, preterm birth, blood pressure disorders, diabetes, and other complications linked to depression in pregnancy, underscoring the need to diagnose and treat depression in pregnant women.

Among more than 1,800 women planning a pregnancy, those who received at least one dose of a COVID-19 vaccine before getting pregnant were no more likely to miscarry than those who were unvaccinated. The study also found no increased miscarriage risk among roughly 1,500 couples in which the male partner was vaccinated before trying to conceive.

NIH will award up to $2 million in cash prizes as part of its Fetal Monitoring Challenge to accelerate development of diagnostic and monitoring technologies that improve fetal health outcomes in low-resource settings. U.S. scientists, engineers, and clinicians can submit innovative approaches and compete for prizes and resources to support technology development and clinical impact, with a focus on point-of-care and home-based diagnostic and monitoring technologies that may reduce fetal health risk and loss during and after birth.

A device known as a pessary, thought promising for reducing preterm birth risk due to a short cervix, appears no more effective than usual medical care, according to a study funded by the National Institutes of Health. A pessary is a rounded silicone device that fits around a cervix that has shortened, to keep it from opening and leading to miscarriage or preterm birth. The device is typically removed before the 37th week of pregnancy.

Read about NICHD’s research findings and activities from 2022.

The Division of Intramural Research provides fundamental knowledge about the nature and behavior of living systems through basic, clinical, and population-based research.

Read about NICHD’s research findings and activities from 2021.

It just got easier to participate in the PregSource®: Crowdsourcing to Understand Pregnancy research project. The free app allows participants to track their weight, sleep, mood, and other features of their pregnancy in just a few taps.

Dr. Grewal has been acting director of the division since February 2020.

Preemptive treatment for a nonviable pregnancy of unknown location resolves the condition more rapidly than treating symptoms as they arise, suggests an NICHD-supported study. However, both treatment approaches convey similar risks of adverse events.

NICHD Director Dr. Diana Bianchi is joined by NIH Office of Research on Women’s Health Director Dr. Janine Clayton in assessing the growing maternal health crisis in the United States and describing NIH’s efforts to address it.

Pregnant women need to be protected through research rather than from research, the authors contend.

As the COVID-19 pandemic persists, SARS-CoV-2 vaccines offer the potential to halt the spread of the virus. Yet, we know very little about the effectiveness and safety of the vaccines during pregnancy.

NIH-funded study suggests mother-to-infant transmission appears to be rare

Contrary to previous findings, low-dose aspirin therapy before conception and during early pregnancy may increase pregnancy chances and live births among women who have experienced one or two prior miscarriages, suggests a study by researchers at the National Institutes of Health. Rather than looking solely at the difference in pregnancy rates between women who were given aspirin and those receiving a placebo, the study also accounted for differences in total aspirin use between women who deviated from the daily regimen and those who adhered to it.

Increased stress may interfere with adjustment to new motherhood, mother-infant bonding